Aqueous Immiscible Layered Double Hydroxides – AIM-Ldhs Kanittika Ruengkajorn, Christopher M

Total Page:16

File Type:pdf, Size:1020Kb

Aqueous Immiscible Layered Double Hydroxides – AIM-Ldhs Kanittika Ruengkajorn, Christopher M Electronic Supplementary Material (ESI) for Materials Chemistry Frontiers. This journal is © the Partner Organisations 2018 Aqueous Immiscible Layered Double Hydroxides – AIM-LDHs Kanittika Ruengkajorn, Christopher M. R. Wright. Nicholas H. Rees, Jean-Charles Buffet and Dermot O’Hare* Chemistry Research Laboratory, University of Oxford, 12 Mansfield Road, OX3 1TA, Oxford. E-mail: [email protected] Table of contents 1. General experimental details S2 1.1. Analytical techniques for LDH characterisation S2 1.2. Synthesis of Conventional, AMO- and AIM-LDHs S4 2. Supplementary experimental data S6 2.1 Figures S6 2.2 Tables S36 3 References S47 S1 1. General experimental details 1.1 Analytical techniques for LDH characterisation 1.1.1. X-ray powder diffraction (XRD) X-ray powder diffraction (XRD) results were investigated by using a PANalytical X’Pert Pro diffractometer in reflection mode operating at a voltage of 40 kV and a current intensity of 40 mA with Cu-Kα radiation (λ = 1.5406 Å). LDHs and LDOs powder were placed into stainless steel sample holders. A 1° slit was used. Bragg reflections due to sample holder were observed at 2θ = 43-44° and 50° and from silicon wafer were located at 2θ = 33°, 62° and 69°. The Scherrer’s equation was used to estimate the mean crystallite domain length (CDL) of the LDHs; CDL = Kλ(βcosθ)-1, where CDL = the mean crystallite domain length, K = Scherrer constant, λ = the wavelength of the radiation, and β = the full-width at half-maximum height (FWHM) values of a reflection located at 2θ. Thus, the CDL along c- axis (CDL003) can be calculated from the full-width at half-maximum height values of the (003) Bragg reflection, which is assumed to be the total crystal thickness along the c-axis. Moreover, a layer thickness of LDHs from the d003 spacing using the Bragg’s law; nλ = 2d(sinθ), n is assumed to be one. Therefore, by application of the Bragg’s law and the Scherrer equation, the number of LDH layers can be estimated. Equation 1. Scherrer equation to determine the mean crystalline domain length (CDL).22 퐶퐷퐿 = 퐾휆(훽푐표푠휃)−1 퐾 = 푆푐ℎ푒푟푟푒푟 푐표푛푠푡푎푛푡 휆 = 푡ℎ푒 푤푎푣푒푙푒푛푔푡ℎ 표푓 푡ℎ푒 푟푎푑푎푡표푛 훽 = 푡ℎ푒 푓푢푙푙-푤푑푡ℎ 푎푡 ℎ푎푙푓-푚푎푥푚푢푚 (퐹푊퐻푀) 푣푎푙푢푒 표푓 푎 푟푒푓푙푒푐푡표푛 푎푡 2휃 1.1.2. Fourier transform infrared spectroscopy (FTIR) Fourier transform infrared (FTIR) spectra of samples were recorded on Thermo Scientific Nicolet iS5 FTIR spectrometer in attenuated total reflectance (ATR) mode. Spectra were obtained in the range of 600-4000 cm−1; 50 scans with 4 cm−1 resolution. 1.1.3. Transmission electron microscopy (TEM) Transmission electron microscopy (TEM) was conducted at the Research Complex at Harwell on Jeol JEM-2100 TEM equipped with LaB6 filament at an accelerlating voltage of 200 kV. Prior to analysis, samples were diluted with deionised water and sonicated in deionised water for 15 minutes. A few droplets of the resulting suspension were left to dry on a copper grid covered with a carbon film (300 mesh, Agar scientific). S2 1.1.4. Scanning electron microscopy (SEM) Scanning electron microscopy (SEM) was carried out at the Research Complex at Harwell on a JSM-6610LV low vacuum fitted with EDX spectrometer at an accelerating voltage of 20 kV. Samples were mounted on adhesive carbon tape attached to aluminium stubs then sputter-coated with a 10 nm layer of platinum using a Quorum Q150T ES Sputter Coater to facilitate image. 1.1.5. Zeta potential and Dynamic light scattering (DLS) measurements Zeta potential measurements and DLS analysis were carried out at the Begbroke Science Park, Department of Materials, University of Oxford. LDH Samples were dispersed and sonicated in deionised water at 0.1 wt% for 15 minutes before measurement. The resulting suspension samples were filled in a folded capillary cell and directly measured by using a using a Malvern Zetasizer Nano ZS. 1.1.6. Specific surface area and pore size analysis Specific surface areas and pore size were analysed using the Brunauer–Emmett–Teller (BET) method. The samples were measured from the N2 adsorption and desorption isotherms at 77 K collected from a Micromeritics TriStar II plus. Before each measurement, LDH samples were first degassed overnight at 110 °C. 1.1.7 Thermogravimetric analysis Thermogravimetric analyses were performed by using a Mettler Toledo TGA/DSC 1 system. 15 mg of sample (LDHs) was loaded into alumina crucible and heated from 30–800 °C at a rate of 5 °C/min under a flow of dry N2. Differential thermogravimetric analysis (DTG) is obtained from the 1st derivative of TGA data. 1.1.8 Elemental analysis (EA) Elemental C, H, N analysis was performed by a quantitative oxidative combustion technique by Mr Stephen Boyer at London Metropolitan University. 1.1.9 Inductively coupled plasma mass spectrometer (ICP-MS) Mg and Al content were determined by ICP-MS analysis by Dr. Alaa Abdul-Sada at the University of Sussex on an Agilent 7500 Series ICP-MS in helium collision mode. Approximately, 20 mg of samples were digested in 10 mL of 10% nitric acid solution. These solutions were then diluted by a factor of 100 with dilute nitric acid prior to analysis. Each solution was analysed three times and the data averaged. 1.1.10 Density Tap densities were determined by standard testing method (ASTM D7481-09) using a graduated cylinder. The powder was filled into a volumetric cylinder and a precise weight of sample (m) was measured. The volume was measured before (V0) and after 1000 taps (Vt). S3 The loose bulk and tap densities were calculated by: Loose bulk density = m/V0; Tap density = m/Vt. 1.1.11 Solid state NMR spectroscopy The 1H, 27Al and 13C solid state NMR spectroscopy were performed by Dr. Nicholas H. Rees (University of Oxford) on a Bruker Avance III HD spectrometer equipped with a 9.4 T magnet using 4.0 mm O.D zirconia rotors and a MAS rate of 10 kHz at 399.9, 104.2, and 100.6 MHz, respectively. The high resolution 1H solid state NMR was performed by Dr. Nicholas H. Rees, Dr. Jean- Charles Buffet and Dr. Christopher M. R. Wright (University of Oxford) and Dr. Dinu Iuga (University of Warwick) at the UK 850 MHz Solid-State NMR Facility at the University of Warwick using the Bruker Avance III 850 MHz solid-state NMR spectrometer with 1.3 mm rotors and MAS rate of 60 kHz at 23°C. 1H experiment with background suppression applied referenced to β-Aspagine-Alanine dipeptide. 1.2 Synthesis of Conventional, AMO and AIM LDHs 1.2.1 Synthesis of flower shape like Mg4Al-CO3 LDHs via co-precipitation method The mixed metal salts solution of Mg(NO3)2·6H2O (80 mmol) and Al(NO3)3·9H2O (20 mmol) in 50 mL deionised water was added dropwise into 50 mL of 25 mmol Na2CO3 solution while stirring for 1 hour. Constant pH of 10 was maintained by addition of 4 M NaOH to the reaction mixture using an auto-titrator (Syrris, Atlas Syringe Pump) at feeding rate of 5 mL/min. After stirring at room temperature for 24 hours, the product was filtered and washed with deionised water until pH 7. Then the wet cake was re-dispersed in 100 mL of deionised water and divided into four portions. Each portion was filtered and rinsed with 500 mL of a washing solvent then re-dispersed and stirred in 300 mL of this solvent at room temperature for 4 hours. The solvent was removed by filtration and the obtained LDH was further rinsed with 200 mL of this solvent. The product was dried at room temperature in a vacuum oven overnight. Mg2Al-CO3 LDH and Mg3Al-CO3 LDH were prepared using similar procedure as mentioned above. The mixed metal solution was prepared using 50 mL aqueous solution of 33.3 and 37.5 mmol of Mg(NO3)2·6H2O and 16.7 and 12.5 mmol of Al(NO3)3·9H2O, for Mg2Al-CO3 LDH and Mg3Al-CO3 LDH, respectively. Then the same procedure as mentioned above was used. 1.2.2 Synthesis of platelets shape like Mg4Al-CO3 LDHs via co-precipitation method Synthesis method for platelet shape Mg4Al-CO3 LDHs was modified from Okamoto et al.. An aqueous solution of Mg(NO3)2·6H2O (40 mmol), Al(NO3)3·9H2O (10 mmol) and urea (160 mmol) in 100 mL deionised water was prepared. The solution was transferred to a Teflon-lined autoclave and heated in an oven at 100 °C for 24 hours. After cooling to room temperature, the precipitate products were washed several times with deionised water by filtration until pH 7. Then the wet cake was re-dispersed in 100 mL of deionised water and S4 separated into four portions. A portion of dispersion was filtered and followed steps as mentioned above. Solvents used were acetone, ethanol, 1-hexanol, and ethyl acetate. 1.2.3. Effect of solvent types: AMO vs. AIM solvents Both AMO and AIM solvents were compared in this study. The AMO solvent was ethanol, the AIM solvents were ethyl acetate, diethyl ether, hexane and toluene. S5 2. Supplementary experimental data 2.1 Figures 003 006 012 113 110 * 015 018 Water Acetone Ethanol Isopropyl alcohol 1-Methyl-2-pyrrolidinone Ethylacetate 1-Butanol 1-Hexanol Triethylamine Nitromethane Methyl ethyl ketone Relative intensity (a.u.) intensity Relative Diethyl ether Tert-butyl methyl ether Toluene Hexane Chloroform 10 20 30 40 50 60 70 2(o) Fig. S1. Powder X-ray diffraction patterns of some solvent-treated Mg4Al–CO3 LDHs. * is a Bragg reflection from the Al sample holder.
Recommended publications
  • Lonsurf (Trifluridine/Tipiracil) Were Bone Marrow Suppression and Gastrointestinal Toxicity
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrLONSURF® trifluridine and tipiracil tablet 15 mg trifluridine/ 6.14 mg tipiracil (as tipiracil hydrochloride) 20 mg trifluridine / 8.19 mg tipiracil (as tipiracil hydrochloride) Antineoplastic Agent Thymidine phosphorylase inhibitor/nucleoside metabolic inhibitor Taiho Pharma Canada, Inc. Date of Initial Approval: 2010 Winston Park Drive, Suite 503 January 23, 2018 Oakville, Ontario L6H 5R7 Canada Submission Control No: 205852 Page 1 of 35 RECENT MAJOR LABEL CHANGES Not Applicable TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES ......................................................................................2 TABLE OF CONTENTS ..............................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION ............................................................4 1 INDICATIONS....................................................................................................................4 1.1 Pediatrics ....................................................................................................................4 1.2 Geriatrics ....................................................................................................................4 2 CONTRAINDICATIONS ..................................................................................................4 3 DOSAGE AND ADMINISTRATION ...............................................................................4 3.1 Dosing Considerations
    [Show full text]
  • These Highlights Do Not Include All the Information Needed to Use LONSURF Safely and Effectively
    LONSURF- trifluridine and tipiracil tablet, film coated Taiho Pharmaceutical Co., Ltd. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LONSURF safely and effectively. See full prescribing information for LONSURF. LONSURF (trifluridine and tipiracil) tablets, for oral use Initial U.S. Approval: 2015 RECENT MAJOR CHANGES Indications and Usage (1.2) 2/2019 Recommended Dosage (2.1) 2/2019 Warnings and Precaution (5.1) 2/2019 INDICATIONS AND USAGE LONSURF is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated for the treatment of adult patients with: metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. (1.1) metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu- targeted therapy. (1.2) DOSAGE AND ADMINISTRATION Recommended Dosage: 35 mg/m2/dose orally twice daily with food on Days 1 through 5 and Days 8 through 12 of each 28-day cycle. (2.1) DOSAGE FORMS AND STRENGTHS Tablets: 15 mg trifluridine/6.14 mg tipiracil (3) 20 mg trifluridine/8.19 mg tipiracil (3) CONTRAINDICATIONS None. (4) WARNINGS AND PRECAUTIONS Severe Myelosuppression: Obtain complete blood counts prior to and on Day 15 of each cycle. Withhold and resume at next lower LONSURF dosage as recommended. (2.1, 5.1) Embryo-Fetal Toxicity: Can cause fetal harm.
    [Show full text]
  • Justification Document for the Selection of a Corap Substance
    JUSTIFICATION DOCUMENT FOR THE SELECTION OF A CORAP SUBSTANCE ________________________________________________________________ Justification Document for the Selection of a CoRAP Substance Substance Name (public name): Diethyl Ether EC Number: 200-467-2 CAS Number: 60-29-7 Authority: France Date: 21/03/2017 Cover Note This document has been prepared by the evaluating Member State given in the CoRAP update. JUSTIFICATION DOCUMENT FOR THE SELECTION OF A CORAP SUBSTANCE _______________________________________________________________ Table of Contents 1 IDENTITY OF THE SUBSTANCE 3 1.1 Other identifiers of the substance 3 2 OVERVIEW OF OTHER PROCESSES / EU LEGISLATION 5 3 HAZARD INFORMATION (INCLUDING CLASSIFICATION) 7 3.1 Classification 7 3.1.1 Harmonised Classification in Annex VI of the CLP 7 3.1.2 Self classification 7 3.1.3 Proposal for Harmonised Classification in Annex VI of the CLP 7 4 INFORMATION ON (AGGREGATED) TONNAGE AND USES 8 4.1 Tonnage and registration status 8 4.2 Overview of uses 8 5. JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CORAP SUBSTANCE 10 5.1. Legal basis for the proposal 10 5.2. Selection criteria met (why the substance qualifies for being in CoRAP) 10 5.3 Initial grounds for concern to be clarified under Substance Evaluation 10 5.4 Preliminary indication of information that may need to be requested to clarify the concern 11 5.5 Potential follow-up and link to risk management 11 EC no 200-467-2 MSCA - France Page 2 of 11 JUSTIFICATION DOCUMENT FOR THE SELECTION OF A CORAP SUBSTANCE _______________________________________________________________
    [Show full text]
  • GRAS Notice 695, Dimethyl Ether
    GRAS Notice (GRN) No. 695 http://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/default.htm Callaghan Sl ~ TECHNOLOGY..,u CESS March 17, 2017 Dr. Paulette Gaynor Office of Food Additive Safety (FHS-200) MAR 2 0 2017 Center for Food Safety and Applied Nutrition Food and Drug Administration OFFICE OF FOOD ADDITIVE SAFETY 5100 Campus Drive College Park, MD 20740 Re: GRAS Notice for Dimethyl Ether Dear Dr. Gaynor In accordance with 21 CFR §170 Subpart E consisting of §170.203 through 170.285, Callaghan Innovation hereby informs the United States Food and Drug Administration of the conclusion that the intended use of dimethyl ether as an extraction solvent in the processing of various food products is Generally Recognized as Safe (GRAS) as described in the enclosed notice, and thereby the intended use of dimethyl ether is not subject to the premarket approval requirements of the Federal Food, Drug, and Cosmetic Act. I hereby certify that the enclosed electronic files were scanned for viruses prior to submission and are thus certified as being virus-free using McAfee VirusScan 8.8. Should you have any questions or concerns regarding this GRAS Notice, please do not hesitate to contact me at any point during the review process so that we may provide a response in a timely manner. Yours sincerely (b) (6) Stephen Tallon, Ph.D. Senior Research Engineer Callaghan Innovation GRAS Notice for the Use of Dimethyl Ether as an Extraction Solvent Prepared for: Office of Food Additive Safety (FHS-200) Center for Food Safety and Applied Nutrition Food and Drug Administration 5100 Campus Drive College Park, MD 20740 Submitted by: Callaghan Innovation 69 Gracefield Road Lower Hutt 5040 New Zealand March 7, 2017 GRAS Notice for the Use of Dimethyl Ether as an Extraction Solvent Table of Contents Page Part 1.
    [Show full text]
  • [Product Monograph Template
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrLONSURF® trifluridine and tipiracil tablet 15 mg trifluridine/ 6.14 mg tipiracil (as tipiracil hydrochloride) 20 mg trifluridine / 8.19 mg tipiracil (as tipiracil hydrochloride) Antineoplastic Agent Thymidine phosphorylase inhibitor/nucleoside metabolic inhibitor Taiho Pharma Canada, Inc. Date of Initial Approval: 2010 Winston Park Drive, Suite 503 January 23, 2018 Oakville, Ontario L6H 5R7 Date of Revision: Canada November 18, 2019 Submission Control No: 227070 Page 1 of 40 RECENT MAJOR LABEL CHANGES INDICATIONS (1) 11-2019 WARNINGS AND PRECAUTIONS (6), Geriatrics (6.1.4) 11-2019 TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES ........................................................................... 2 TABLE OF CONTENTS ................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ................................................... 4 1 INDICATIONS ..................................................................................................... 4 1.1 Pediatrics .................................................................................................... 4 1.2 Geriatrics .................................................................................................... 4 2 CONTRAINDICATIONS ...................................................................................... 4 3 DOSAGE AND ADMINISTRATION .................................................................... 4 3.1 Dosing Considerations...............................................................................
    [Show full text]
  • Auspar Attachment 1: Product Information: Trifluridine/Tipiracil
    Attachment 1: Product information for AusPAR Lonsurf and Orcantas Servier Laboratories Australia Pty Ltd PM-2016-00929-1-4 Final 12 June 2018. This Product Information was approved at the time this AusPAR was published. LONSURF (trifluridine/tipiracil) – Product Information 1 (20) Product Information NAME OF THE MEDICINE LONSURF 15/6.14 Trifluridine 15 mg/ tipiracil hydrochloride 7.065 mg (equivalent to tipiracil 6.14 mg) LONSURF 20/8.19 Trifluridine 20 mg/ tipiracil hydrochloride 9.420 mg (equivalent to tipiracil 8.19 mg) The active components of LONSURF are trifluridine and tipiracil hydrochloride. Trifluridine Trifluridine has the chemical name 2′-deoxy-5-(trifluoromethyl)uridine Chemical structure: Molecular formula: C10H11F3N2O5 (Relative Molecular Mass: 296.20) CAS Registry Number: 70-00-8 Tipiracil hydrochloride Tipiracil hydrochloride has the chemical name 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine- 2,4-(1H,3H)-dione monohydrochloride. Chemical structure: Molecular formula: C9H11ClN4O2•HCl (Relative Molecular Mass: 279.12) CAS Registry Number: 183204-72-0 DESCRIPTION Trifluridine is a white crystalline powder, soluble in water, ethanol, 0.01 mol/L hydrochloric acid, 0.01 mol/L sodium hydroxide solution; freely soluble in methanol, acetone; sparingly soluble in 2- propanol, acetonitrile; slightly soluble in diethyl ether; and very slightly soluble in isopropyl ether. Tipiracil hydrochloride is a white crystalline powder, soluble in water, 0.01 mol/L hydrochloric acid, and 0.01 mol/L sodium hydroxide; slightly soluble in methanol; very slightly soluble in ethanol; and practically insoluble in acetonitrile, 2-propanol, acetone, diisopropyl ether, and diethyl ether. Version 1 Attachment 1: Product information for AusPAR Lonsurf and Orcantas Servier Laboratories Australia Pty Ltd PM-2016-00929-1-4 Final 12 June 2018.
    [Show full text]
  • Product Monograph
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrLONSURF® trifluridine and tipiracil tablet 15 mg trifluridine/ 6.14 mg tipiracil (as tipiracil hydrochloride) 20 mg trifluridine / 8.19 mg tipiracil (as tipiracil hydrochloride) Antineoplastic Agent Thymidine phosphorylase inhibitor/nucleoside metabolic inhibitor Taiho Pharma Canada, Inc. Date of Initial Approval: 2010 Winston Park Drive, Suite 503 JAN 23, 2018 Oakville, Ontario L6H 5R7 Date of Revision: Canada OCT 29, 2020 Submission Control No: 235999 Page 1 of 37 RECENT MAJOR LABEL CHANGES INDICATIONS (1) 11-2019 WARNINGS AND PRECAUTIONS (6), Geriatrics (6.1.4) 11-2019 DOSAGE AND ADMINISTRATION (3.3) 10-2020 WARNINGS AND PRECAUTIONS (6), Renal 10-2020 TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES ........................................................................... 2 TABLE OF CONTENTS ................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ................................................... 4 1 INDICATIONS ..................................................................................................... 4 1.1 Pediatrics .................................................................................................... 4 1.2 Geriatrics .................................................................................................... 4 2 CONTRAINDICATIONS ...................................................................................... 4 3 DOSAGE AND ADMINISTRATION ...................................................................
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8.445,002 B2 Mansouri (45) Date of Patent: May 21, 2013
    USOO8445002B2 (12) United States Patent (10) Patent No.: US 8.445,002 B2 Mansouri (45) Date of Patent: May 21, 2013 (54) DERMAL DELIVERY COMPOSITIONS (56) References Cited COMPRISING ACTIVE AGENT-CALCUM PHOSPHATE PARTICLE COMPLEXES AND U.S. PATENT DOCUMENTS METHODS OF USING THE SAME 4,948,575 A * 8/1990 Cole et al. ....................... 424/44 5,158,756 A * 10/1992 Ogawa et al. ...... ... 423.309 (75) Inventor: Zahra Mansouri, Tahoe City, CA (US) 5,604.200 A * 2/1997 Taylor-McCord ............. 514/9.3 6,096,324 A 8, 2000 Mansouri 6,120,782 A 9, 2000 Mansouri (73) Assignee: Laboratory Skin Care, Inc., Tahoe 6,262,020 B1* T/2001 Lezdey et al. .................. 514/5.9 City, CA (US) 6,395,311 B2* 5/2002 Jia .................. ... 424/744 6,573.249 B2 * 6/2003 Lezdey et al. ................... 514/54 (*) Notice: Subject to any disclaimer, the term of this 2002fOO18797 A1 2/2002 Cui et al. patent is extended or adjusted under 35 2005/00 13874 A1 1/2005 Ito et al. ........................ 424,602 2005/02341 14 A1 10, 2005 Lee U.S.C. 154(b) by 0 days. 2006/0257658 A1* 11/2006 Tanaka et al. ................. 428/402 2007, OOO3487 A1* 1/2007 Ek ............... ... 424/46 (21) Appl. No.: 12/742,235 2008/005.1335 A1 2/2008 Kleiner et al. .................. 514/12 2008, 0220233 A1 9/2008 Kjellin et al. (22) PCT Filed: May 6, 2010 2010/0086606 A1* 4/2010 Ogawa .......................... 424/489 2012/0130435 A1* 5, 2012 Hart et al. ...... ... 606,301 (86). PCT No.: PCT/US2O10/033942 2012/0134919 A1* 5/2012 Engqvist et al.
    [Show full text]
  • Targets in Heterocyclic Systems
    Italian Society of Chemistry Division of Organic Chemistry Division of Medicinal Chemistry Division of Mass Spectrometry TARGETS IN HETEROCYCLIC SYSTEMS Chemistry and Properties Volume 17 (2013) Reviews and Accounts on Heterocyclic Chemistry http://www.soc.chim.it/it/libriecollane/target_hs Editors Prof. Orazio A. Attanasi University of Urbino “Carlo Bo”, Urbino, Italy and Prof. Domenico Spinelli University of Bologna, Bologna, Italy Published by: Società Chimica Italiana Viale Liegi, 48 00198 Roma Italy ___________________________________________________________________________ Copyright © 2013 Società Chimica Italiana All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means (electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise) without permission in writing from the publishers. A person may photocopy an article for personal use. Volume 1 (1997) First edition 1997 ISBN 88-86208-24-3 Second edition 1999 ISBN 88-86208-24-3 Volume 2 (1998) First edition 1999 ISBN 88-86208-11-1 Volume 3 (1999) First edition 2000 ISBN 88-86208-13-8 Volume 4 (2000) First edition 2001 ISBN 88-86208-16-2 Volume 5 (2001) First edition 2002 ISBN 88-86208-19-7 Volume 6 (2002) First edition 2003 ISBN 88-86208-23-5 Volume 7 (2003) First edition 2004 ISBN 88-86208-28-6 ISSN 1724-9449 Volume 8 (2004) First edition 2005 ISBN 88 86208-29-4 ISSN 1724-9449 Volume 9 (2005) First edition 2006 ISBN 88 86208-31-6 ISSN 1724-9449 Volume 10 (2006) First edition
    [Show full text]
  • WO 2019/002407 Al 03 January 2019 (03.01.2019) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2019/002407 Al 03 January 2019 (03.01.2019) W !P O PCT (51) International Patent Classification: Near Gangotri Circle, Nikol, Ahmedabad Gujarat 382350 C07D 403/06 (2006.01) A61K 31/513 (2006.01) (IN). SAVALIYA, Bhavesh Laljibhai; At: Itali, Men- A61P 35/00 (2006.01) darda, Junagadh Gujarat 362260 (IN). KOILPILLAI, Joseph Prabahar; H-56, TNHB Phase-II, Perumalpu- (21) International Application Number: ram, Tirunelveli, Tamil Nadu 627007 (IN). AGARW- PCT/EP20 18/067322 AL, Virendra Kumar; A14, Vishal residency, Anandna- (22) International Filing Date: gar charrasta, Satellite, Ahmedabad Gujarat 380015 (IN). 27 June 2018 (27.06.2018) CHAVAN, Rahul Baburao; 525, Manisha Nivas, Nanded road, Ahmedpur, Maharashtra 4135 15 (IN). ARABIANI, (25) Filing Language: English Mohsin Razakbhai; 32A Gulzar Park Gate No. 1, Opp. Es- (26) Publication Language: English sar Petrol Pump, Sarkhej Juhapura Road, Ahmedabad Gu jarat 380055 (IN). HEDAPARA, Kalpesh Ratilal; B-205, (30) Priority Data: Shreenidhi apartment, Haridarshan road, Ahmedabad Gu 201721022621 28 June 2017 (28.06.2017) jarat 382350 (IN). KATARIYA, Lalit Keshav; D-102, 201721022621 26 June 2018 (26.06.2018) Garden Residency 2, Behind Shyam villa, Ahmedabad Gu (71) Applicant: AMNEAL PHARMACEUTICALS COM¬ jarat 380058 (IN). PATEL, Vijay Premajibhai; A-20, PANY GMBH [CH/CH]; Turmstrasse 30, 63 12 Stein- Shivalik society, Patel street, Bayad Gujarat 383335 (IN). hausen (CH). THUMMAR, Mahesh Kurajibhai; L-204, Nilkanth or chid, Sterling city, Bopal, Ahmedabad Gujarat 380058 (IN). (72) Inventors: MAHETA, Abhay Subodhbhai; F-302, Bi- BHALODIYA, Rahul Harsukhlal; 1-504, Prathna lavish, nori sonnet, , Near Govt.
    [Show full text]
  • Peroxide Forming Chemicals to Counter Peroxide Formation
    Peroxide-Forming Chemicals Overview Peroxide-forming chemicals are a class of compounds that have the ability to form shock-sensitive explosive peroxide crystals. Many of the organic solvents commonly used in laboratories have the potential to form explosive peroxide crystals. Diethyl ether and tetrahydrofuran are two of the more common peroxide- forming chemicals used today. Therefore, it is extremely important that this procedure be followed regarding the identification, handling, storage, and disposal of peroxide-forming chemicals. Peroxide Formation Under normal storage conditions the materials listed in this document have the potential to generate and accumulate peroxide crystal formations, which may violently detonate when subjected to thermal or mechanical shock. Peroxide-forming chemicals react with oxygen – even at low concentrations – to form peroxy compounds. The risk associated with peroxide formation increases if the peroxide crystallizes or becomes concentrated by evaporation or distillation. Factors that affect rate of peroxide formation include exposure to air, light and heat, moisture, and contamination from metals. Manufacturers may add an inhibitor to peroxide forming chemicals to counter peroxide formation. For many peroxide-forming solvents, butylated hydroxy toluene (BHT) is commonly added. BHT ‘scavenges’ oxygen in the solvent and prevents it from reacting with the solvent to form peroxides. Over time, BHT or other inhibitor in the solvent can become exhausted allowing peroxides to form. Distilling the solvent can completely remove the BHT and make the solvent immediately susceptible to peroxide formation. Peroxide crystals may form on the container plug or the threads of the lid and detonate when the lid is twisted. Do not open a liquid organic peroxide or peroxide-forming chemical if crystals or a precipitate are present.
    [Show full text]
  • Deperoxidation of Ethers. a Novel Application of Self-Indicating Molecular Sieves
    J. Org. Chem. 1982,47,3821-3824 3821 under Nz for 3.5 h in an oil bath maintained at 100 "C. The (B) Aromatization of Enone 15 to 2,2-Difluoro-4- reaction mixture was poured onto an excess of ice, and after the hydroxybenzocyclobutenone (16). A solution of enone 15 (2.25 ice had melted HzO was added to bring the total volume to 1500 g, 9.2 mmol) in 60 mL of MeOH was cooled to 0 "C in a 250-mL mL. The solution was extracted with CHzClz(5 X 100 mL), and round-bottomed flask and the solution was saturated with dry the combined organic layers were extracted with saturated N2 for 5 min. The flask was fitted with a pressure equalizing NaHC03 untiI the extracts were colorless. The combined NaHC03 addition funnel and a nitrogen inlet tube and the addition funnel extracts were back-washed with CHzC12 (100 mL) and then was charged with a solution freshly prepared from sodium (0.846 acidified to pH 1 with 12 M HCl. The product was extracted into g, 36.8 mmol) and MeOH (30 mL). The NaOMeIMeOH solution CHzClz(5 X 100 mL), the organic layer was dried (Na2SO4)and was added dropwise with stirring over 30 min, and after the filtered, and solvent was removed on a rotary evaporator followed addition was complete, the reaction mixture was allowed to warm by a vacuum pump to yield 6.3 g of 3-hydroxy-5-methylbenzo- to room temperature and stirred an additional 3 h. An equal cyclobutenedione in 63% overall yield from dienophile 5: light volume of 1.2 N HCl(90 mL) was added, and the mixture was yellow crys&, mp 191-193 OC (EtOAc);IR (CHzC12)3540,1789, refluxed for 3 h to hydrolyze the intermediate ketal.
    [Show full text]